| 000 | 01721 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250517132030.0 | ||
| 264 | 0 | _c20170405 | |
| 008 | 201704s 0 0 eng d | ||
| 022 | _a1432-0614 | ||
| 024 | 7 |
_a10.1007/s00253-016-8063-x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aChandramohan, Vidyalakshmi | |
| 245 | 0 | 0 |
_aProduction and quality control assessment of a GLP-grade immunotoxin, D2C7-(scdsFv)-PE38KDEL, for a phase I/II clinical trial. _h[electronic resource] |
| 260 |
_bApplied microbiology and biotechnology _cApr 2017 |
||
| 300 |
_a2747-2766 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aADP Ribose Transferases _xgenetics |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aBacterial Toxins _xgenetics |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 | _aClinical Trials, Phase I as Topic |
| 650 | 0 | 4 | _aClinical Trials, Phase II as Topic |
| 650 | 0 | 4 | _aDrug Stability |
| 650 | 0 | 4 | _aElectrophoresis, Polyacrylamide Gel |
| 650 | 0 | 4 |
_aErbB Receptors _xgenetics |
| 650 | 0 | 4 |
_aEscherichia coli _xgenetics |
| 650 | 0 | 4 |
_aExotoxins _xgenetics |
| 650 | 0 | 4 | _aFermentation |
| 650 | 0 | 4 |
_aGlioblastoma _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunotoxins _xchemistry |
| 650 | 0 | 4 | _aQuality Control |
| 650 | 0 | 4 |
_aVirulence Factors _xgenetics |
| 650 | 0 | 4 | _aPseudomonas aeruginosa Exotoxin A |
| 700 | 1 | _aPegram, Charles N | |
| 700 | 1 | _aPiao, Hailan | |
| 700 | 1 | _aSzafranski, Scott E | |
| 700 | 1 | _aKuan, Chien-Tsun | |
| 700 | 1 | _aPastan, Ira H | |
| 700 | 1 | _aBigner, Darell D | |
| 773 | 0 |
_tApplied microbiology and biotechnology _gvol. 101 _gno. 7 _gp. 2747-2766 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00253-016-8063-x _zAvailable from publisher's website |
| 999 |
_c26729852 _d26729852 |
||